Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Epilepsy | Treatment Algorithms: Claims Data Analysis | Generalized-Onset Seizures | US | 2019
DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS). The most commonly prescribed early-line treatments for GOS are older antiepileptic drugs (…
Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2018
Heart failure with preserved ejection fraction (HFpEF) occurs due to abnormal relaxation and filling of the left ventricle. Despite the fact that HFpEF accounts for nearly half of all CHF cases,…
Attention-Deficit/Hyperactivity Disorder | Current Treatment: Physician Insights | Pediatric ADHD | US | 2019
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Treatment options include a mix of stimulants (e.g.,…
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Current Treatment: Physician Insights – Pediatric ADHD (US)
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Treatment options include a mix of stimulants (e.g.,…
Gastroesophageal Reflux Disease | Treatment Algorithms: Claims Data Analysis | US | 2019
Gastroesophageal reflux disease (GERD) is arguably the most common chronic gastrointestinal disorder, characterized by symptoms of heartburn and regurgitation. The primary objectives of GERD…
Growth Hormone Deficiency | Treatment Algorithms: Claims Data Analysis | Growth Hormone Disorders | US | 2019
Growth hormone is an endogenous hormone produced by the pituitary gland; a deficiency in its production or activity is characterized by short stature, decreased capacity for exercise, and…
Ovarian Cancer – Access & Reimbursement – Access & Reimbursement – Ovarian Cancer (US)
The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (…
Treatment Algorithms US Claims Data Analysis | Acute Coronary Syndrome: Secondary Prevention | US | April 2019
This analysis focuses on the posthospital, secondary prevention of acute coronary syndrome (ACS), which typically involves the implementation of antithrombotic, neurohormonal blocking, and lipid-…
